Billing it as the biotechnology industry's biggest ever drug deal, Genmab A/S licensed the human monoclonal antibody HuMax-CD20 (ofatumumab) to GlaxoSmithKline plc in a transaction with a total potential value exceeding DKK12 billion (US$2.1 billion) and a guaranteed amount of about DKK2.6 billion. (BioWorld International) Read More
